Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747523 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 44
- Enrollment target
NCT03747523: Completed Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
NCT03747523 is a Early Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 44 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03747523, a Early Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.
Primary Outcome
Plasma mucin-1 levels will be measured in both groups. using a two-tailed T-test.
Interventions
- DRUG Ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2020-01-27 |
| Phase | Early Phase 1 |
What the finished NCT03747523 record still lists
NCT03747523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 1 intervention - of which Ergocalciferol is the first listed.
NCT03747523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03747523 about?
NCT03747523 is a clinical study titled "Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels". To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.
What is the current status of trial NCT03747523?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2019-03-12. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT03747523?
The interventions under investigation include: Ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT03747523?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03747523's enrollment target sits among peer trials
44 589th of 2000 higher than 1,401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI